Monday , April 24 2017
Home / Technology & Devices

Technology & Devices

Novartis Enters Deal to Use Parvus’ Navacim Technology to Develop and Commercialize Type 1 Diabetes Drugs

CALGARY, Alberta–(BUSINESS WIRE)–Parvus Therapeutics, a biopharmaceutical company developing disease-modifying nanomedicines to halt or reverse autoimmune disease without causing general immune suppression, has entered into a license and collaboration agreement with Novartis for its lead Navacim for treating type 1 diabetes. Navacims constitute a novel pharmacological class of therapeutic comprised of …

Read More »

Bristol-Myers Squibb and Nordic Bioscience Collaborate for Fibrosis Biomarker Technology

NEW YORK & HERLEV, Denmark–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) and Nordic Bioscience, a Danish company specializing in biomarker technologies, today announced a collaboration agreement to develop biomarker technology to potentially aid in the diagnosis and monitoring of fibrotic diseases including Non-alcoholic steatohepatitis (NASH). Nordic Bioscience has over 25 years’ experience …

Read More »

Abbott Expands Diagnostics Business with $5.3 Billion Acquisition of Alere

ABBOTT PARK, Ill. and WALTHAM, Mass., April 14, 2017 /PRNewswire/ — Abbott (NYSE: ABT) and Alere Inc. (NYSE: ALR) announced today that the companies have agreed to amend the existing terms of their agreement for Abbott’s acquisition of Alere. Under the amended terms, Abbott will pay $51 per common share to …

Read More »

Nanopores Could Map Small Changes in DNA that Signal Big Shifts in Cancer

CHAMPAIGN, Ill. — Detecting cancer early, just as changes are beginning in DNA, could enhance diagnosis and treatment as well as further our understanding of the disease. A new study by University of Illinois researchers describes a method to detect, count and map tiny additions to DNA called methylations, which …

Read More »

USPSTF Seeks Comments on Draft Recommendation Statement on Prostate Cancer Screening

WASHINGTON, April 11, 2017 /PRNewswire/ — The U.S. Preventive Services Task Force today posted for public comment a draft recommendation statement and three draft evidence reviews on screening for prostate cancer. Through this draft recommendation, the Task Force is providing clinicians and their patients with information to help guide decisions …

Read More »

Janssen and PeptiDream Enter $1.15 Billion Drug Discover Deal

TOKYO–(BUSINESS WIRE)–PeptiDream Inc., a public Tokyo-based biopharmaceutical company (“PeptiDream”)(TOKYO: 4587) announced today that it has entered into a multi-target discovery and optimization collaboration with US-based Janssen Pharmaceuticals, Inc. (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ). Under the agreement, facilitated by Johnson & Johnson Innovation, …

Read More »

FDA Approves 23andMe’s At-Home DNA Test to Predict Risk for 10 Diseases

The U.S. Food and Drug Administration today allowed marketing of 23andMe Personal Genome Service Genetic Health Risk (GHR) tests for 10 diseases or conditions. These are the first direct-to-consumer (DTC) tests authorized by the FDA that provide information on an individual’s genetic predisposition to certain medical diseases or conditions, which …

Read More »

The Skin Cancer Screening Paradigm; Reviewing Current Guidelines for Detecting Melanoma

The Future Science Group (FSG) journal Melanoma Management, today announces the publication of a new perspective article, in which over 50 leaders in the dermatology field critically assess current screening practice for melanoma in the US. Presently, the safest and most cost-effective method of screening for melanoma, a deadly form …

Read More »

Registries Indicate that Many Node-Positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype Dx Results

REDWOOD CITY, Calif., March 24, 2017 /PRNewswire/ — Genomic Health, Inc. (Nasdaq: GHDX) today announced the publication of results from the National Cancer Institute’s (NCI) Surveillance, Epidemiology, and End Results (SEER) Registry in the peer-reviewed journal Breast Cancer Research and Treatment, reconfirming the value of the Oncotype DX Breast Recurrence …

Read More »

Facial Recognition Software Helps Diagnose Rare Genetic Disease

Researchers with the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health, and their collaborators, have successfully used facial recognition software to diagnose a rare, genetic disease in Africans, Asians and Latin Americans. The disease, 22q11.2 deletion syndrome, also known as DiGeorge syndrome and velocardiofacial syndrome, …

Read More »